Since the first application in cancer therapy, monoclonal antibody (MAb) is shown of promising therapeutic effect. In spite of classical mechanism of actions exerted by MAb, such as neutralization, blocking, CDC, ADCC, therapeutic antibody could also act as agonists of the receptors, essentially replacing the activity of the normal ligand.https://www.creativebiolabs.net/agonistic-antibody_72.htm